Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 13, Number 2—February 2007


Neutralizing Antibodies after Infection with Dengue 1 Virus

Gustavo Kourí*Comments to Author , Mayling Alvarez*, Rosmari Rodriguez-Roche*, Lídice Bernardo*, Tibaire Montes†, Susana Vazquez*, Luis Morier*, Angel Alvarez*, Ernest A Gould‡, Maria G. Guzman*Comments to Author , and Scott B Halstead§
Author affiliations: *“Pedro Kourí” Tropical Medicine Institute, Havana, Cuba; †Instituto Medicina Tropical, Caracas, Venezuela; ‡Centre for Ecology and Hydrology, Oxford, United Kingdom; §Pediatric Dengue Vaccine Initiative, Bethesda, Maryland, USA;

Main Article

Table 2

Neutralization of dengue viruses by dengue virus 1–immune serum collected 4–8 years (group 1) and 20–22 years (group 2) after primary infection*

Serotype (strain)Group 1
Group 2
Positivity (%)GMTPositivity (%)GMT
DENV-1 (Jamaica/77)50 (100)9389 (100)140.6
DENV-2 (A15/81)6 (12)5.519 (21)6.5
DENV-2 (I348600)36 (72)†3040 (45)‡10.2
DENV-3 (116/00)4 (8)5.69 (10)5.9
DENV-4 (Dominica)1 (2)5.113 (15)6.2

*GMT, geometric mean titer; DENV, dengue virus.

†p<0.00001 compared with DENV-2 (A15/81), DENV-3, and DENV-4 viruses in group 1.

‡p<0.01–0.0001 compared with DENV-2 (A15/81), DENV-3, and DENV-4 viruses in group 2.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO